| Project/Area Number |
22K14742
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 35030:Organic functional materials-related
|
|---|
| Research Institution | Nagasaki University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2022-04-01 – 2026-03-31
|
| Project Status |
Granted (Fiscal Year 2023)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2025: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2024: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2023: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2022: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | cancer therapy / noble metal / prodrug / templated crystallize / nanomedicine / nanodrugs / metallic cluster / reprecipitation / crystallization |
|---|
| Outline of Research at the Start |
The research proposal aims to be the first establishment of hybrid prodrug nanocrystals with morphology controlled by templated crystallization in the presence of noble metallic nanoparticles, to achieve self-delivery and on-demand drug release.
The obtained hybrid prodrug nanoparticles (NPs) are expected to: (i) Advance the traditional prodrug NPs to a multifunctional system with controllable drug release and designable targeting; and (ii) Provide a facile protocol to fabricate hybrid nanomaterials that size, shape, composition, and properties can be tuned.
|
| Outline of Annual Research Achievements |
The purpose of this research is to design and fabricate a carrier-free nanodrug via templated-crystallization method using SN-38, the active metabolite of irinotecan, acts as a potent inhibitor of DNA topoisomerase I. In this work, several derivatives of SN-38 were selected as the anticancer moiety, and Au cluster of ca. 10 nm was selected as a template. The nanodrugs are fabricated by reprecipitation method.
The formation yield of the hybrid nanodrugs were improved by adjusting the reprecipitation conditions, such as the good solvent of Au nanoparticles. The morphology of Au/SN-38Chol nanoparticles was confirmed SEM and showed a narrow size distribution and template-guided shape. Photothermal effect was investigated and exhibited a sufficient performance in comparison to pure Au nanoparticles.
|
| Current Status of Research Progress |
Current Status of Research Progress
1: Research has progressed more than it was originally planned.
Reason
The second targets of the research plan are close to being complete, including observation of charge transfer effect between noble metal nanoparticles and drug molecules. The research is progressing to the profiling of the drug release kinetic at different conditions.
|
| Strategy for Future Research Activity |
The next targets of the research are investigation of charge transfer effect by UV-Vis, XPS, and FT-IR. The results are correlated with the drug release rate and composition of SN-38 hybrid NPs.
|
